# ![@FierceBiotech Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::18294197.png) @FierceBiotech FierceBiotech

FierceBiotech posts on X about eli lilly, sanofi, $lly, up to the most. They currently have [-------] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

### Engagements: [-----] [#](/creator/twitter::18294197/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::18294197/c:line/m:interactions.svg)

- [--] Week [------] -11%
- [--] Month [-------] +179%
- [--] Months [-------] +60%
- [--] Year [-------] +1.70%

### Mentions: [--] [#](/creator/twitter::18294197/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::18294197/c:line/m:posts_active.svg)

- [--] Month [--] +54%
- [--] Months [---] +38%
- [--] Year [---] -6.80%

### Followers: [-------] [#](/creator/twitter::18294197/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::18294197/c:line/m:followers.svg)

- [--] Week [-------] +0.03%
- [--] Month [-------] +0.08%
- [--] Months [-------] +0.40%
- [--] Year [-------] +0.62%

### CreatorRank: [-------] [#](/creator/twitter::18294197/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::18294197/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  51.11% [finance](/list/finance)  15.56% [currencies](/list/currencies)  3.7% [countries](/list/countries)  2.96% [technology brands](/list/technology-brands)  1.48% [travel destinations](/list/travel-destinations)  1.48% [exchanges](/list/exchanges)  0.74% [cryptocurrencies](/list/cryptocurrencies)  0.74%

**Social topic influence**
[eli lilly](/topic/eli-lilly) #51, [sanofi](/topic/sanofi) #33, [$lly](/topic/$lly) #40, [up to](/topic/up-to) 4.44%, [in the](/topic/in-the) 4.44%, [ceo](/topic/ceo) 4.44%, [$mrna](/topic/$mrna) #10, [$amgn](/topic/$amgn) #65, [$azn](/topic/$azn) #115, [acquisition](/topic/acquisition) #575

**Top accounts mentioned or mentioned by**
[@mikeycolombia33](/creator/undefined) [@jamespharma](/creator/undefined) [@fiercepharma](/creator/undefined) [@varro_analytics](/creator/undefined) [@pearlf](/creator/undefined) [@stockwatch369](/creator/undefined) [@gabriellemasso9](/creator/undefined) [@megadarren](/creator/undefined) [@fiercehealth](/creator/undefined) [@damianfierce](/creator/undefined) [@pharmaceuticben](/creator/undefined) [@mikengladstone](/creator/undefined) [@zailab_global](/creator/undefined) [@johnyacex](/creator/undefined) [@billygains01](/creator/undefined) [@mike98572986](/creator/undefined)

**Top assets mentioned**
[Eli Lilly and Company (LLY)](/topic/eli-lilly) [Sanofi (SNY)](/topic/sanofi) [Moderna Inc (MRNA)](/topic/$mrna) [Amgen, Inc. (AMGN)](/topic/$amgn) [AstraZeneca PLC (AZN)](/topic/$azn) [Synthetify (SNY)](/topic/$sny) [Pfizer, Inc. (PFE)](/topic/$pfe) [Johnson & Johnson (JNJ)](/topic/$jnj) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Novartis AG (NVS)](/topic/$nvs) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Novo-Nordisk (NVO)](/topic/$nvo) [GSK plc (GSK)](/topic/$gsk) [Intellia Therapeutics, Inc (NTLA)](/topic/$ntla) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Zenas BioPharma, Inc. (ZBIO)](/topic/$zbio) [Instil Bio, Inc. (TIL)](/topic/$til) [Wave Life Sciences Ltd. Ordinary Shares (WVE)](/topic/$wve) [Disc Medicine, Inc. Common Stock (IRON)](/topic/$iron) [MEI Pharma, Inc. (MEIP)](/topic/mei-pharma) [Biogen Inc (BIIB)](/topic/$biib) [Sage Therapeutics, Inc (SAGE)](/topic/$sage) [AbbVie Inc (ABBV)](/topic/$abbv) [Incyte Corporation (INCY)](/topic/$incy) [Acadia Pharmaceuticals Inc. (ACAD)](/topic/$acad) [Neumora Therapeutics, Inc. (NMRA)](/topic/$nmra) [Corcept Therapeutics Inc. (CORT)](/topic/$cort) [Bicara Therapeutics Inc. (BCAX)](/topic/$bcax) [Arrowhead Research Corporation (ARWR)](/topic/$arwr) [Celldex Therapeutics, Inc (CLDX)](/topic/$cldx)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Takeda ispaying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal whichincludes $10.2 billion in milestones puts the biologics at the center of Takedas push to establish growth drivers for the post-Entyvio era. https://www.fiercebiotech.com/biotech/takeda-pays-innovent-12b-upfront-rights-2-cancer-candidates https://www.fiercebiotech.com/biotech/takeda-pays-innovent-12b-upfront-rights-2-cancer-candidates"  
[X Link](https://x.com/FierceBiotech/status/1980998776308617656)  2025-10-22T14:04Z 101.8K followers, 10.9K engagements


"Chinese life science contracting giant WuXi AppTec is taking another step to zero in on its core offerings by hiving off two China-based subsidiaries. https://www.fiercebiotech.com/cro/wuxi-apptec-sharpens-focus-selling-clinical-research-units https://www.fiercebiotech.com/cro/wuxi-apptec-sharpens-focus-selling-clinical-research-units"  
[X Link](https://x.com/FierceBiotech/status/1983217737498247481)  2025-10-28T17:02Z 101.8K followers, [----] engagements


"A phase [--] study of Zenas' autoimmune disease candidate hashit its primary endpoint. But with the result falling short of the bar Amgen set in another study the biotech's stock halved in value as markets opened. $ZBIO https://www.fiercebiotech.com/biotech/zenas-indigo-data-leaves-wall-street-feeling-blue-despite-primary-endpoint-hit https://www.fiercebiotech.com/biotech/zenas-indigo-data-leaves-wall-street-feeling-blue-despite-primary-endpoint-hit"  
[X Link](https://x.com/FierceBiotech/status/2008188580586525138)  2026-01-05T14:47Z 101.8K followers, [----] engagements


"Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing company Seamless Therapeutics. $LLY https://www.fiercebiotech.com/biotech/lilly-pens-11b-pact-german-biotech-work-gene-editing-med-hearing-loss https://www.fiercebiotech.com/biotech/lilly-pens-11b-pact-german-biotech-work-gene-editing-med-hearing-loss"  
[X Link](https://x.com/FierceBiotech/status/2016515813365231795)  2026-01-28T14:16Z 101.8K followers, [----] engagements


"With three Big Pharma collaborations already under its belt Flagship spinout Repertoire has picked up another pactits biggest yet. https://www.fiercebiotech.com/biotech/repertoire-adds-eli-lilly-its-range-big-pharma-partners-85m-upfront-autoimmune-pact https://www.fiercebiotech.com/biotech/repertoire-adds-eli-lilly-its-range-big-pharma-partners-85m-upfront-autoimmune-pact"  
[X Link](https://x.com/FierceBiotech/status/2016895857208025477)  2026-01-29T15:26Z 101.8K followers, [----] engagements


"Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine Fierce has learned that the French pharma has put this pipeline on ice. Scoop from @JamesPharma https://www.fiercebiotech.com/biotech/sanofi-scraps-attempt-develop-next-gen-mrna-seasonal-flu-vaccine https://www.fiercebiotech.com/biotech/sanofi-scraps-attempt-develop-next-gen-mrna-seasonal-flu-vaccine"  
[X Link](https://x.com/FierceBiotech/status/2016897183002366153)  2026-01-29T15:32Z 101.8K followers, [----] engagements


"Novartis is paying $1.4 billion to get its hands on Tourmaline Bio and its ex-Pfizer cardiovascular drug that impressed in a phase [--] study earlier this year. $NVS https://www.fiercebiotech.com/biotech/novartis-spends-13b-tourmaline-and-cardiovascular-med-impressed-phase-2 https://www.fiercebiotech.com/biotech/novartis-spends-13b-tourmaline-and-cardiovascular-med-impressed-phase-2"  
[X Link](https://x.com/FierceBiotech/status/1965421300371128820)  2025-09-09T14:25Z 101.8K followers, [----] engagements


"Daiichi Sankyo and Merck & Co.s phase [--] program for their investigational antibody-drug conjugate has been hit with a hold after an unexpected number of deaths were reported in the global trial. $MRK https://www.fiercebiotech.com/biotech/patient-deaths-prompt-partial-hold-daiichi-mercks-global-phase-3-adc-program https://www.fiercebiotech.com/biotech/patient-deaths-prompt-partial-hold-daiichi-mercks-global-phase-3-adc-program"  
[X Link](https://x.com/FierceBiotech/status/2001692679541797183)  2025-12-18T16:34Z 101.8K followers, 11.7K engagements


"Instil Bios hopes for its refreshed clinical pipeline appear to have ended in failure with the U.S. biotech handing the rights to two drugs back to their original owner. $TIL https://www.fiercebiotech.com/biotech/instils-stock-sinks-after-clearing-out-clinical-pipeline-handing-2-drugs-back-immuneonco https://www.fiercebiotech.com/biotech/instils-stock-sinks-after-clearing-out-clinical-pipeline-handing-2-drugs-back-immuneonco"  
[X Link](https://x.com/FierceBiotech/status/2008556835528474861)  2026-01-06T15:10Z 101.8K followers, [----] engagements


"Amgen is adding Dark Blue to its tapestry embedding the U.K. biotechs preclinical blood cancer program into its organization for up to $840 million. https://www.fiercebiotech.com/biotech/amgen-stitches-new-acquisition-worth-840m-biotechs-blood-cancer-program https://www.fiercebiotech.com/biotech/amgen-stitches-new-acquisition-worth-840m-biotechs-blood-cancer-program"  
[X Link](https://x.com/FierceBiotech/status/2008567495414972891)  2026-01-06T15:53Z 101.8K followers, [----] engagements


"Adding Merck & Co. and Modernas vaccine candidate to Keytrudahas continued to cut the risk of cancer recurrence or death across five years of follow-up boosting the companies prospects as they close in on phase [--] data. $MRNA $MRK https://www.fiercebiotech.com/biotech/merck-moderna-cancer-vaccine-sustains-49-melanoma-risk-reduction-5-years https://www.fiercebiotech.com/biotech/merck-moderna-cancer-vaccine-sustains-49-melanoma-risk-reduction-5-years"  
[X Link](https://x.com/FierceBiotech/status/2013638901156716736)  2026-01-20T15:45Z 101.8K followers, [----] engagements


"When Genenta Science listed on the Nasdaq at the tail end of [----] the Milan-based biotech was squarely focused on its pipeline of cell-based gene therapies. But four years later the company is taking the business in an unexpected direction. https://www.fiercebiotech.com/biotech/gene-therapies-firearms-italian-biotech-makes-unexpected-strategic-pivot https://www.fiercebiotech.com/biotech/gene-therapies-firearms-italian-biotech-makes-unexpected-strategic-pivot"  
[X Link](https://x.com/FierceBiotech/status/2016207629131919439)  2026-01-27T17:52Z 101.8K followers, [----] engagements


"A brain tumor has prompted the FDA toplace clinical holds on two Regenxbio gene therapies including a candidate that is less than two weeks away from an approval decision. $RGNX https://www.fiercebiotech.com/biotech/fda-puts-clinical-hold-regenxbio-gene-therapies-weeks-approval-ruling https://www.fiercebiotech.com/biotech/fda-puts-clinical-hold-regenxbio-gene-therapies-weeks-approval-ruling"  
[X Link](https://x.com/FierceBiotech/status/2016522928402088331)  2026-01-28T14:45Z 101.8K followers, [----] engagements


"Amgen hasterminated its rocatinlimab collaboration with Kyowa Kirin walking away from the anti-OX40 antibody five years afterpaying $400 million for rights to the autoimmune disease drug candidate. $AMGN https://www.fiercebiotech.com/biotech/amgen-jilts-kyowa-exiting-400m-autoimmune-pact-after-running-vast-pivotal-program https://www.fiercebiotech.com/biotech/amgen-jilts-kyowa-exiting-400m-autoimmune-pact-after-running-vast-pivotal-program"  
[X Link](https://x.com/FierceBiotech/status/2017268603263864876)  2026-01-30T16:08Z 101.8K followers, [----] engagements


"AstraZeneca hasoutlined plans to invest $15 billion in China through [----] making a broad commitment to enhance capabilities in areas including cell therapies and radioconjugates. $AZN https://www.fiercebiotech.com/biotech/astrazeneca-vows-15b-china-investment-boost-cell-therapy-and-radioconjugate-capabilities https://www.fiercebiotech.com/biotech/astrazeneca-vows-15b-china-investment-boost-cell-therapy-and-radioconjugate-capabilities"  
[X Link](https://x.com/FierceBiotech/status/2016877414203142351)  2026-01-29T14:13Z 101.8K followers, [----] engagements


"The ink was barely dry on AstraZenecas announcement of a landmark investment in its Chinese capabilities before the U.K.-based pharma agreed to pay more than $1 billion upfront in an obesity deal with China's CSPC. $AZN https://www.fiercebiotech.com/biotech/astrazeneca-returns-chinas-cspc-47b-obesity-deal https://www.fiercebiotech.com/biotech/astrazeneca-returns-chinas-cspc-47b-obesity-deal"  
[X Link](https://x.com/FierceBiotech/status/2017267599558513136)  2026-01-30T16:04Z 101.8K followers, [----] engagements


"Sanofis pipeline features a number of once-hyped candidates that are struggling to deliver in the clinic and the latest mixed phase [--] data from venglustat continue this trend. $SNY https://www.fiercebiotech.com/biotech/sanofis-troubled-gcs-inhibitor-fails-phase-3-fabry-trial-wins-gaucher-disease https://www.fiercebiotech.com/biotech/sanofis-troubled-gcs-inhibitor-fails-phase-3-fabry-trial-wins-gaucher-disease"  
[X Link](https://x.com/FierceBiotech/status/2018333105992368515)  2026-02-02T14:38Z 101.8K followers, [----] engagements


"As autologous CAR-T continues to improve and Big Pharma pumps big cash into next-gen approaches is there room left at the table for allogeneic CAR-T https://www.fiercebiotech.com/biotech/only-thing-saves-us-data-allogeneic-car-t-biotechs-fight-relevance-industry-moves https://www.fiercebiotech.com/biotech/only-thing-saves-us-data-allogeneic-car-t-biotechs-fight-relevance-industry-moves"  
[X Link](https://x.com/FierceBiotech/status/2021629519799693719)  2026-02-11T16:56Z 101.8K followers, [----] engagements


"Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands as partner GSK has decided not to take over development of the experimental oligonucleotide. $WVE https://www.fiercebiotech.com/biotech/wave-regains-rights-genetic-disease-rna-editor-gsk https://www.fiercebiotech.com/biotech/wave-regains-rights-genetic-disease-rna-editor-gsk"  
[X Link](https://x.com/anyuser/status/2018360912852234289)  2026-02-02T16:28Z 101.8K followers, [----] engagements


"Novo Nordisks GLP-1/amylin combo has topped blockbuster semaglutide in a phase [--] Type [--] diabetes trial though CagriSema still didn't hit the 25% weight loss mark that the pharma had previously laid out for its next-gen asset. $NVO https://www.fiercebiotech.com/biotech/novos-cagrisema-tops-semaglutide-ph-3-diabetes-study-still-falls-short-25-weight-loss-goal https://www.fiercebiotech.com/biotech/novos-cagrisema-tops-semaglutide-ph-3-diabetes-study-still-falls-short-25-weight-loss-goal"  
[X Link](https://x.com/anyuser/status/2018432807421297048)  2026-02-02T21:14Z 101.8K followers, [----] engagements


"Patients in a phase 2b trialkept losing weight after switching to monthly dosing of Pfizers GLP-1 receptor agonist providing early validation of the drugmakers $10 billion bet on Metsera. $PFE https://www.fiercebiotech.com/biotech/pfizers-10b-monthly-glp-1-bet-generates-competitive-weight-loss-phase-2b https://www.fiercebiotech.com/biotech/pfizers-10b-monthly-glp-1-bet-generates-competitive-weight-loss-phase-2b"  
[X Link](https://x.com/anyuser/status/2018687913651753124)  2026-02-03T14:07Z 101.8K followers, [----] engagements


"Luke Miels had only been at the helm of GSK for [--] days when he signed off on his first multibillion-dollar buyout. https://www.fiercebiotech.com/biotech/gsks-new-ceo-looking-2-4b-deals-hiding-plain-sight https://www.fiercebiotech.com/biotech/gsks-new-ceo-looking-2-4b-deals-hiding-plain-sight"  
[X Link](https://x.com/FierceBiotech/status/2019067297676079430)  2026-02-04T15:15Z 101.8K followers, [----] engagements


"Amgens bad luck in lupus may finally be coming to an end as a monoclonal antibody acquired from Horizon Therapeutics hit the primary endpoint in a phase [--] trial. $AMGN https://www.fiercebiotech.com/biotech/amgen-advances-toward-lupus-redemption-while-gastric-cancer-candidate-struggles https://www.fiercebiotech.com/biotech/amgen-advances-toward-lupus-redemption-while-gastric-cancer-candidate-struggles"  
[X Link](https://x.com/anyuser/status/2019104302459957568)  2026-02-04T17:42Z 101.8K followers, [----] engagements


"Eli Lilly has discarded three clinical-stage drugs including a gene therapy from its $1 billion acquisition of Prevail Therapeutics. $LLY https://www.fiercebiotech.com/biotech/lilly-drops-3-pipeline-drugs-including-gene-therapy-1b-prevail-buyout https://www.fiercebiotech.com/biotech/lilly-drops-3-pipeline-drugs-including-gene-therapy-1b-prevail-buyout"  
[X Link](https://x.com/anyuser/status/2019106892623278086)  2026-02-04T17:52Z 101.8K followers, 23.8K engagements


"By signing a government funding bill that ended a partial shutdown President Trump has also reauthorized a program meant to speed the development of new drugs for rare childhood diseases. @FiercePharma https://www.fiercepharma.com/pharma/fdas-rare-pediatric-disease-voucher-program-revived-2026-government-funding-bill https://www.fiercepharma.com/pharma/fdas-rare-pediatric-disease-voucher-program-revived-2026-government-funding-bill"  
[X Link](https://x.com/anyuser/status/2019414205183525093)  2026-02-05T14:14Z 101.8K followers, [----] engagements


"Eli Lilly has become the latest Big Pharma to buy itself a corner of the in vivo CAR-T space via the acquisition of Orna Therapeutics for up to $2.4 billion. $LLY https://www.fiercebiotech.com/biotech/lilly-buys-orna-24b-enter-vivo-car-t-arena https://www.fiercebiotech.com/biotech/lilly-buys-orna-24b-enter-vivo-car-t-arena"  
[X Link](https://x.com/FierceBiotech/status/2020861935604879785)  2026-02-09T14:06Z 101.8K followers, [----] engagements


"Busy day for Lilly as the pharma inks a separate deal with China's Innovent. The heavily backloaded pact could reach a total of $8.5 billion biobucks. https://www.fiercebiotech.com/biotech/lilly-innovent-pen-88b-collab-moves-beyond-traditional-licensing https://www.fiercebiotech.com/biotech/lilly-innovent-pen-88b-collab-moves-beyond-traditional-licensing"  
[X Link](https://x.com/anyuser/status/2020875332782272995)  2026-02-09T15:00Z 101.8K followers, [----] engagements


"After facing a delay and clinical hold Regenxbios Hunter syndrome gene therapy has been rejected by the FDA. Fierce interviews with CMO Steve Pakola and gene therapy pioneer Jim Wilson here $RGNX https://www.fiercebiotech.com/biotech/fda-rejects-regenxbio-hunter-syndrome-gene-therapy-recently-hit-hold-unrelated-brain-tumor https://www.fiercebiotech.com/biotech/fda-rejects-regenxbio-hunter-syndrome-gene-therapy-recently-hit-hold-unrelated-brain-tumor"  
[X Link](https://x.com/FierceBiotech/status/2020971218917274068)  2026-02-09T21:21Z 101.8K followers, [----] engagements


"Moderna has issued a sharp rebuke of the FDA's rationale for refusing the company's next-gen flu vaccine for approval consideration. $MRNA https://www.fiercebiotech.com/biotech/moderna-hit-fda-refusal-file-letter-mrna-flu-shot-issues-sharp-rebuke-agencys-rationale https://www.fiercebiotech.com/biotech/moderna-hit-fda-refusal-file-letter-mrna-flu-shot-issues-sharp-rebuke-agencys-rationale"  
[X Link](https://x.com/FierceBiotech/status/2021600669786866142)  2026-02-11T15:02Z 101.8K followers, [----] engagements


"Following Moderna's public rebuke of the FDA's refusal to take up its application for a next-gen flu vaccine the regulator has doubled down. $MRNA https://www.fiercebiotech.com/biotech/after-facing-modernas-ire-fda-stands-behind-decision-spurn-mrna-flu-filing https://www.fiercebiotech.com/biotech/after-facing-modernas-ire-fda-stands-behind-decision-spurn-mrna-flu-filing"  
[X Link](https://x.com/FierceBiotech/status/2021682040001708331)  2026-02-11T20:25Z 101.8K followers, [----] engagements


"Sanofi hasreplaced its CEO Paul Hudson after a series of R&D setbacks at the French pharma handing the reins to Merck KGaA leader Beln Garijo M.D. Ph.D. $SNY https://www.fiercepharma.com/pharma/sanofi-ousts-paul-hudson-after-bumpy-ride-poaches-merck-kgaa-ceo-lead-company https://www.fiercepharma.com/pharma/sanofi-ousts-paul-hudson-after-bumpy-ride-poaches-merck-kgaa-ceo-lead-company"  
[X Link](https://x.com/FierceBiotech/status/2021952427172544521)  2026-02-12T14:19Z 101.8K followers, [----] engagements


"Mere months after laying off a quarter of its workforce to fund a phase [--] study of its bloodstream infection preventive treatment Seres Therapeutics is pausing that investment and sending 30% of staffers out the door. $MCRB https://www.fiercebiotech.com/biotech/seres-lay-30-employees-pause-lead-program-latest-strategic-shift https://www.fiercebiotech.com/biotech/seres-lay-30-employees-pause-lead-program-latest-strategic-shift"  
[X Link](https://x.com/FierceBiotech/status/2021963171041620465)  2026-02-12T15:02Z 101.8K followers, [----] engagements


"Two experts have told Fierce's @JamesPharma that they're expecting around 30-35 biotech IPOs for [----]. If Im wrong I'm guessing I'm wrong because I'm too conservative Milestone Advisors Matt Lane said. https://www.fiercebiotech.com/biotech/when-markets-opened-we-were-ready-why-biotech-ipos-are-back-2026 https://www.fiercebiotech.com/biotech/when-markets-opened-we-were-ready-why-biotech-ipos-are-back-2026"  
[X Link](https://x.com/FierceBiotech/status/2022303565096612039)  2026-02-13T13:35Z 101.8K followers, [----] engagements


"On this episode of "The Top Line" Fierce Biotech's James Waldron and Fierce Pharma's Fraiser Kansteiner discuss the clinical trial failures that stood out in [----]. https://omny.fm/shows/the-top-line/what-were-the-biggest-clinical-trial-flops-of-2025 https://omny.fm/shows/the-top-line/what-were-the-biggest-clinical-trial-flops-of-2025"  
[X Link](https://x.com/FierceBiotech/status/2022360705102422274)  2026-02-13T17:22Z 101.8K followers, [----] engagements


"The FDA has rejected a rare blood disease candidate from Disc Medicine a compound that had been granted expedited review through a newly launched priority voucher program. $IRON https://www.fiercebiotech.com/biotech/fda-rejects-discs-rare-disease-drug-despite-commissioners-voucher https://www.fiercebiotech.com/biotech/fda-rejects-discs-rare-disease-drug-despite-commissioners-voucher"  
[X Link](https://x.com/FierceBiotech/status/2022431011615957482)  2026-02-13T22:01Z 101.8K followers, [----] engagements


"Johnson & Johnson has presented phase [--] data on nipocalimab in generalized myasthenia gravis providing a look at how its $6.5 billion prospect matches up to the approved FcRn rivals from argenx and UCB. $JNJ https://www.fiercebiotech.com/biotech/jj-unwraps-pivotal-data-65b-autoimmune-it-prepares-crash-argenx-and-ucbs-party https://www.fiercebiotech.com/biotech/jj-unwraps-pivotal-data-65b-autoimmune-it-prepares-crash-argenx-and-ucbs-party"  
[X Link](https://x.com/FierceBiotech/status/1807777773701747142)  2024-07-01T14:06Z 101.7K followers, [----] engagements


"Merck & Co. is expanding a research partnership with Orion into an exclusive licensing pact putting more than $1.6 billion biobucks on the table for cancer candidates targeting CYP11A1. https://www.fiercebiotech.com/biotech/merck-co-opts-orions-hormone-dependent-cancer-candidates https://www.fiercebiotech.com/biotech/merck-co-opts-orions-hormone-dependent-cancer-candidates"  
[X Link](https://x.com/FierceBiotech/status/1807804837981274232)  2024-07-01T15:53Z 101.7K followers, [----] engagements


"Three people with autoimmune diseases have responded positively to allogeneic CAR-T therapy marking a first for the "off-the-shelf" cell therapy tech. https://www.fiercebiotech.com/biotech/allogeneic-car-t-cells-used-treat-autoimmune-disease-first-time https://www.fiercebiotech.com/biotech/allogeneic-car-t-cells-used-treat-autoimmune-disease-first-time"  
[X Link](https://x.com/FierceBiotech/status/1813673669077659975)  2024-07-17T20:34Z 101.7K followers, [----] engagements


"Layoffs at GlycoMimetics Anokion and Relay Therapeutics. Scoops from @GabrielleMasso9 and @MegaDarren here https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024 https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024"  
[X Link](https://x.com/FierceBiotech/status/1816582542239367241)  2024-07-25T21:13Z 101.7K followers, [----] engagements


"Moderna co-founder Langer leaves board as David Rubenstein joins. Charles Baum takes over Terremoto. MEI Pharma says goodbye to CEO CMO. https://www.fiercebiotech.com/biotech/chutes-ladders-moderna-co-founder-robert-langer-leaves-board-philanthropist-david https://www.fiercebiotech.com/biotech/chutes-ladders-moderna-co-founder-robert-langer-leaves-board-philanthropist-david"  
[X Link](https://x.com/FierceBiotech/status/1816836442124861665)  2024-07-26T14:02Z 101.7K followers, [----] engagements


"Denali reports new method to get antisense oligonucleotides across blood-brain barrier https://www.fiercebiotech.com/research/denali-reports-new-method-get-antisense-oligonucleotides-across-blood-brain-barrier https://www.fiercebiotech.com/research/denali-reports-new-method-get-antisense-oligonucleotides-across-blood-brain-barrier"  
[X Link](https://x.com/FierceBiotech/status/1824144205683241337)  2024-08-15T18:00Z 101.7K followers, [----] engagements


"BridgeBio Pharma isslashing its gene therapy budget and pulling back from the modality after seeing the results of a phase 1/2 clinical trial. https://www.fiercebiotech.com/biotech/bridgebio-slashes-gene-therapy-budget-after-early-phase-data-fall-short-transformational https://www.fiercebiotech.com/biotech/bridgebio-slashes-gene-therapy-budget-after-early-phase-data-fall-short-transformational"  
[X Link](https://x.com/FierceBiotech/status/1833862546018722270)  2024-09-11T13:37Z 101.7K followers, [----] engagements


"Biogen has scrapped an alliance with Sage Therapeutics in the aftermath of a failed study that precluded further development in essential tremor. $BIIB https://www.fiercebiotech.com/biotech/biogen-cans-sage-324-collaboration-after-essential-tremor-fail https://www.fiercebiotech.com/biotech/biogen-cans-sage-324-collaboration-after-essential-tremor-fail"  
[X Link](https://x.com/FierceBiotech/status/1839305608664924301)  2024-09-26T14:06Z 101.7K followers, [----] engagements


"Acadia brings BMS vet on board as CEO. Abiologics adds exec expertise with new CSO. Century Therapeutics shakes up leadership https://www.fiercebiotech.com/biotech/chutes-ladders-acadia-brings-bms-vet-board-ceo https://www.fiercebiotech.com/biotech/chutes-ladders-acadia-brings-bms-vet-board-ceo"  
[X Link](https://x.com/FierceBiotech/status/1839667529171513551)  2024-09-27T14:04Z 101.7K followers, [----] engagements


"Sage Therapeutics has called time on its plans to develop dalzanemdor in Alzheimers disease afterseeing midphase data adding to an earlier Parkinsons flop. $SAGE https://www.fiercebiotech.com/biotech/sage-scraps-alzheimers-program-dalzanemdor-goes-0-2-leaving-hopes-resting-huntingtons https://www.fiercebiotech.com/biotech/sage-scraps-alzheimers-program-dalzanemdor-goes-0-2-leaving-hopes-resting-huntingtons"  
[X Link](https://x.com/FierceBiotech/status/1843668335873143097)  2024-10-08T15:02Z 101.7K followers, [----] engagements


"Sage Therapeutics latest attempt to shrink its pipeline and workforce will see a third of the biotechs employees heading for the exits along with a swath of the company's leadership. https://www.fiercebiotech.com/biotech/sage-lays-half-rd-team-and-shakes-c-suite-again https://www.fiercebiotech.com/biotech/sage-lays-half-rd-team-and-shakes-c-suite-again"  
[X Link](https://x.com/FierceBiotech/status/1846929314232537151)  2024-10-17T15:00Z 101.7K followers, [----] engagements


"AbbVie hasacquired Aliada Therapeutics for $1.4 billion a deal that will give the pharma control of an Alzheimers disease drug candidate designed to improve on the first generation of anti-amyloid-beta antibodies. https://www.fiercebiotech.com/biotech/abbvie-inks-14b-aliada-buyout-landing-ex-jj-alzheimers-drug-leap-blood-brain-barrier https://www.fiercebiotech.com/biotech/abbvie-inks-14b-aliada-buyout-landing-ex-jj-alzheimers-drug-leap-blood-brain-barrier"  
[X Link](https://x.com/FierceBiotech/status/1850905029273604483)  2024-10-28T14:18Z 101.7K followers, [----] engagements


"Bayer has become the latest in a long line of drug developers to give up on Huntingtons disease after the German pharma giant dropped its clinical-stage gene therapy for the disease. https://www.fiercebiotech.com/biotech/bayer-drops-huntingtons-gene-therapy-focus-most-promising-assets https://www.fiercebiotech.com/biotech/bayer-drops-huntingtons-gene-therapy-focus-most-promising-assets"  
[X Link](https://x.com/FierceBiotech/status/1856421170846777455)  2024-11-12T19:37Z 101.7K followers, [----] engagements


"A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgens market cap. $AMGN https://www.fiercebiotech.com/biotech/hidden-data-obesity-prospect-wipe-12b-amgen-market-cap https://www.fiercebiotech.com/biotech/hidden-data-obesity-prospect-wipe-12b-amgen-market-cap"  
[X Link](https://x.com/FierceBiotech/status/1856707642783105356)  2024-11-13T14:36Z 101.7K followers, [----] engagements


"BioNTech is paying $800 million upfront to buy its partner Biotheus and secure full rights to a leading prospect in the immuno-oncology space. $BNTX https://www.fiercebiotech.com/biotech/biontech-pays-800m-take-control-potential-keytruda-killer https://www.fiercebiotech.com/biotech/biontech-pays-800m-take-control-potential-keytruda-killer"  
[X Link](https://x.com/FierceBiotech/status/1856727765665329196)  2024-11-13T15:56Z 101.7K followers, [----] engagements


"Incytes $750M Escient Pharmaceuticals buyout has rapidly run into problems. Less than six months after closing the deal Incyte haspaused a key study over preclinical toxicology findings and axed another program altogether. $INCY https://www.fiercebiotech.com/biotech/incytes-750m-buyout-rocked-pause-key-trial-asset-cull https://www.fiercebiotech.com/biotech/incytes-750m-buyout-rocked-pause-key-trial-asset-cull"  
[X Link](https://x.com/FierceBiotech/status/1858882476032115170)  2024-11-19T14:38Z 101.7K followers, [----] engagements


"Novartis has slimmed down its clinical-stage programs by nearly 40% in recent years as the Big Pharma took to heart data that didn't demonstrate a good return from its medicines according to CEO Vas Narasimhan. $NVS https://www.fiercebiotech.com/biotech/novartis-took-data-heart-slimming-clinical-pipeline-40-says-ceo https://www.fiercebiotech.com/biotech/novartis-took-data-heart-slimming-clinical-pipeline-40-says-ceo"  
[X Link](https://x.com/FierceBiotech/status/1859637371563549033)  2024-11-21T16:37Z 101.7K followers, [----] engagements


"Acadia Pharmaceuticals has penned an exclusive licensing deal worth up to $582 million biobucks for Sanionas neurological disorder asset. https://www.fiercebiotech.com/biotech/acadia-nabs-rights-sanionas-tremor-asset-582m-biobucks-deal https://www.fiercebiotech.com/biotech/acadia-nabs-rights-sanionas-tremor-asset-582m-biobucks-deal"  
[X Link](https://x.com/FierceBiotech/status/1861800820380946571)  2024-11-27T15:54Z 101.7K followers, [----] engagements


"Corcept Therapeutics selective cortisol modulatorfailed to slow the progress of ALS in a phase [--] trial and was also linked to substantially more gastrointestinal upset. https://www.fiercebiotech.com/biotech/corcepts-cortisol-modulator-fails-slow-als-decline-linked-gastrointestinal-upset https://www.fiercebiotech.com/biotech/corcepts-cortisol-modulator-fails-slow-als-decline-linked-gastrointestinal-upset"  
[X Link](https://x.com/FierceBiotech/status/1867240499939029467)  2024-12-12T16:10Z 101.7K followers, [----] engagements


"The first of three late-stage readouts on Neumoras lead drug candidate hasended in failure wiping more than 80% off the value of the biotech. $NMRA https://www.fiercebiotech.com/biotech/neumora-stumbles-start-phase-3-depression-readout-run-sending-stock-down-80 https://www.fiercebiotech.com/biotech/neumora-stumbles-start-phase-3-depression-readout-run-sending-stock-down-80"  
[X Link](https://x.com/FierceBiotech/status/1874856077252309468)  2025-01-02T16:31Z 101.2K followers, [----] engagements


"I-Mab has begun the new year with a pipeline pivot pausing work on an asset Sanofi bought into last year to focus on its play for the congested CLDN18.2 space. $IMAB $SNY https://www.fiercebiotech.com/biotech/i-mab-pauses-sanofi-partnered-prospect-make-play-busy-cldn182-space https://www.fiercebiotech.com/biotech/i-mab-pauses-sanofi-partnered-prospect-make-play-busy-cldn182-space"  
[X Link](https://x.com/FierceBiotech/status/1876315824052740401)  2025-01-06T17:12Z 101.7K followers, [----] engagements


"Roche has about $10 billion in M&A firepower it can deploy every year but its not just going to spend money the companys pharma CEO Teresa Graham said at the J.P. Morgan Healthcare Conference. https://www.fiercebiotech.com/biotech/roche-has-10b-ma-firepower-year-pharma-ceo-says-where-will-it-spend-money https://www.fiercebiotech.com/biotech/roche-has-10b-ma-firepower-year-pharma-ceo-says-where-will-it-spend-money"  
[X Link](https://x.com/FierceBiotech/status/1879230302243148268)  2025-01-14T18:13Z 101.7K followers, 10.8K engagements


"Leap Therapeutics has come crashing down to earth. The biotech axed plans to advance into phase [--] in gastric cancer on the basis of midstage data sending its stock down 60% to below $1 but it is forging ahead in another indication. $LPTX https://www.fiercebiotech.com/biotech/leap-crashes-midphase-data-mark-end-gastric-cancer-program https://www.fiercebiotech.com/biotech/leap-crashes-midphase-data-mark-end-gastric-cancer-program"  
[X Link](https://x.com/FierceBiotech/status/1884259571801416183)  2025-01-28T15:17Z 101.2K followers, [----] engagements


"Eli Lilly has thinned its pipelineaxing clinical-phase Alzheimers disease and obesity candidates as part of its quarterly clear-out. $LLY https://www.fiercebiotech.com/biotech/eli-lilly-lops-alzheimers-and-obesity-assets-pipeline-q4-update https://www.fiercebiotech.com/biotech/eli-lilly-lops-alzheimers-and-obesity-assets-pipeline-q4-update"  
[X Link](https://x.com/FierceBiotech/status/1887522321360908324)  2025-02-06T15:22Z 101.2K followers, [----] engagements


"Buying Alexion remains a fantastic acquisition for AstraZeneca the Big Pharmas CEO has said even as the company takes a $753 million hit for abandoning one of the drugs from the buyout. $AZN https://www.fiercebiotech.com/biotech/astrazeneca-resets-big-bets-taking-1b-charges-ex-alexion-fusion-assets-suffer-setbacks https://www.fiercebiotech.com/biotech/astrazeneca-resets-big-bets-taking-1b-charges-ex-alexion-fusion-assets-suffer-setbacks"  
[X Link](https://x.com/FierceBiotech/status/1887530787429380096)  2025-02-06T15:56Z 101.7K followers, [----] engagements


"Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle disease trial ahead of a planned push to regulators. https://www.fiercebiotech.com/biotech/sanofi-backed-acuro-raises-200m-series-c-fund-pivotal-trial-klrg1-antibody https://www.fiercebiotech.com/biotech/sanofi-backed-acuro-raises-200m-series-c-fund-pivotal-trial-klrg1-antibody"  
[X Link](https://x.com/FierceBiotech/status/1889692246817091904)  2025-02-12T15:05Z 101.2K followers, [----] engagements


"A year and a half after Sanofi swooped in on Johnson & Johnsons dismantled vaccines unit to pick up an E. coli candidate the asset has failed its phase [--] trial. https://www.fiercebiotech.com/biotech/sanofi-takes-250m-hit-after-gamble-jj-e-coli-vaccine-ends-phase-3-failure https://www.fiercebiotech.com/biotech/sanofi-takes-250m-hit-after-gamble-jj-e-coli-vaccine-ends-phase-3-failure"  
[X Link](https://x.com/FierceBiotech/status/1890043535182962860)  2025-02-13T14:21Z 101.2K followers, [----] engagements


"A trial of Modernas norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological disorder. $MRNA https://www.fiercebiotech.com/biotech/modernas-norovirus-vaccine-placed-fda-hold-over-case-guillain-barre https://www.fiercebiotech.com/biotech/modernas-norovirus-vaccine-placed-fda-hold-over-case-guillain-barre"  
[X Link](https://x.com/FierceBiotech/status/1890403262379036712)  2025-02-14T14:10Z 101.2K followers, [----] engagements


"AstraZeneca has entered the off-the-shelf cell therapy space penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. $AZN https://www.fiercebiotech.com/biotech/astrazeneca-goes-vivo-penning-1b-deal-belgian-lentiviral-vector-cell-therapy-biotech https://www.fiercebiotech.com/biotech/astrazeneca-goes-vivo-penning-1b-deal-belgian-lentiviral-vector-cell-therapy-biotech"  
[X Link](https://x.com/FierceBiotech/status/1901622674444435500)  2025-03-17T13:12Z 101.7K followers, [----] engagements


"Corcept Therapeutics oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to chemotherapy alone in a phase [--] trial. $CORT"  
[X Link](https://x.com/FierceBiotech/status/1906730320897941664)  2025-03-31T15:28Z 101.7K followers, [----] engagements


"Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. $LLY https://www.fiercebiotech.com/biotech/lillys-oral-glp-1-drug-delivers-ozempic-efficacy-phase-3-diabetes-trial https://www.fiercebiotech.com/biotech/lillys-oral-glp-1-drug-delivers-ozempic-efficacy-phase-3-diabetes-trial"  
[X Link](https://x.com/FierceBiotech/status/1912860535109869813)  2025-04-17T13:27Z 101.7K followers, [----] engagements


"Scholar Rock shakes up C-suite. NIH acting directors take the stage. Engine revs up with new CSO. 🪂🪜 https://www.fiercebiotech.com/biotech/chutes-ladders-scholar-rock-rocks-boat-new-execs https://www.fiercebiotech.com/biotech/chutes-ladders-scholar-rock-rocks-boat-new-execs"  
[X Link](https://x.com/FierceBiotech/status/1918290237811507260)  2025-05-02T13:03Z 101.7K followers, [----] engagements


"Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover blowing a hole in its oncology R&D pipeline in the process. $TAK https://www.fiercebiotech.com/biotech/takeda-shoots-down-bispecifics-bagged-maverick-buyout-amid-cancer-candidate-clearout https://www.fiercebiotech.com/biotech/takeda-shoots-down-bispecifics-bagged-maverick-buyout-amid-cancer-candidate-clearout"  
[X Link](https://x.com/FierceBiotech/status/1920465896977428642)  2025-05-08T13:08Z 101.7K followers, 10.3K engagements


"Almost all the patients with depression who received Gilgamesh Pharmaceuticals psychedelic drug candidatewent into remission. https://www.fiercebiotech.com/biotech/gilgamesh-links-psychedelic-90-remission-rate-midphase-depression-trial https://www.fiercebiotech.com/biotech/gilgamesh-links-psychedelic-90-remission-rate-midphase-depression-trial"  
[X Link](https://x.com/FierceBiotech/status/1927392305104798162)  2025-05-27T15:51Z 101.7K followers, 15.4K engagements


"Intellia Therapeutics stock may have taken a hit in the wake of details of a grade [--] adverse event in a phase [--] trial but analysts are keeping faith in the gene therapys wider safety profile. $NTLA https://www.fiercebiotech.com/biotech/intellias-stock-sinks-gene-therapy-patients-raised-enzyme-levels-analysts-keep-faith https://www.fiercebiotech.com/biotech/intellias-stock-sinks-gene-therapy-patients-raised-enzyme-levels-analysts-keep-faith"  
[X Link](https://x.com/FierceBiotech/status/1928090396724232374)  2025-05-29T14:05Z 101.7K followers, [----] engagements


"Bicara is sharing updated data for its bifunctional antibody plus Keytruda in head and neck squamous cell carcinoma including a first look at OS data for HPV-negative patients as the biotech enrolls for a pivotal trial in the indication. $BCAX https://www.fiercebiotech.com/biotech/asco-bicara-ties-antibody-46-2-year-survival-rate-hnscc-subset https://www.fiercebiotech.com/biotech/asco-bicara-ties-antibody-46-2-year-survival-rate-hnscc-subset"  
[X Link](https://x.com/FierceBiotech/status/1929527814836953323)  2025-06-02T13:17Z 101.8K followers, [----] engagements


"Eli Lilly is walking through the Gate inking a deal worth up to $856 million with a biotech aiming to build out a new small-molecule drug class. $LLY https://www.fiercebiotech.com/biotech/lilly-opens-gate-new-small-molecule-drug-class-856m-biobucks-deal https://www.fiercebiotech.com/biotech/lilly-opens-gate-new-small-molecule-drug-class-856m-biobucks-deal"  
[X Link](https://x.com/FierceBiotech/status/1948468225601073582)  2025-07-24T19:40Z 101.8K followers, [----] engagements


"Xoma Royalty kicked off the week by buying up a pair of biotechs that have both struggled to recover from recent clinical setbacks. $XOMA https://www.fiercebiotech.com/biotech/xoma-goes-shopping-struggling-biotechs-picking-hillevax-and-lava https://www.fiercebiotech.com/biotech/xoma-goes-shopping-struggling-biotechs-picking-hillevax-and-lava"  
[X Link](https://x.com/FierceBiotech/status/1952391233814380654)  2025-08-04T15:28Z 101.7K followers, [----] engagements


"Bicycle Therapeutics is reducing its headcount by around 25% to extend its cash runway into [----]. The layoffs follow Genentechs termination of an oncology collaboration with the biotech. $BCYC https://www.fiercebiotech.com/biotech/bicycle-lays-25-workforce-genentech-rides-away-rd-pact https://www.fiercebiotech.com/biotech/bicycle-lays-25-workforce-genentech-rides-away-rd-pact"  
[X Link](https://x.com/FierceBiotech/status/1953828909872549920)  2025-08-08T14:41Z 101.7K followers, [----] engagements


"Sarepta is selling off Arrowhead shares to stretch its cash runway while also inking a share transfer to pay off half of a $100 million payment owed to the latter. $SRPT $ARWR https://www.fiercebiotech.com/biotech/sarepta-sells-174m-arrowhead-stock-stretch-cash-runway-transfers-shares-pay-half-milestone https://www.fiercebiotech.com/biotech/sarepta-sells-174m-arrowhead-stock-stretch-cash-runway-transfers-shares-pay-half-milestone"  
[X Link](https://x.com/FierceBiotech/status/1955748933713412217)  2025-08-13T21:50Z 101.7K followers, [----] engagements


"Celldex hasstopped development of its experimental antibody in eosinophilic esophagitis despite meeting its primary endpoint in a phase [--] trial. $CLDX https://www.fiercebiotech.com/biotech/celldex-ends-esophageal-program-despite-hitting-primary-endpoint https://www.fiercebiotech.com/biotech/celldex-ends-esophageal-program-despite-hitting-primary-endpoint"  
[X Link](https://x.com/FierceBiotech/status/1958134474090181105)  2025-08-20T11:50Z 101.8K followers, [----] engagements


"The FDAs recent rebuff of Replimunes melanoma candidate has prompted one biotech to stop a clinical trial evaluating a similar drug. $KRYS $REPL https://www.fiercebiotech.com/biotech/krystal-discontinues-melanoma-trial-after-fdas-replimune-rebuff-stat https://www.fiercebiotech.com/biotech/krystal-discontinues-melanoma-trial-after-fdas-replimune-rebuff-stat"  
[X Link](https://x.com/FierceBiotech/status/1958570156294025627)  2025-08-21T16:41Z 101.7K followers, [----] engagements


"Mere months after its cancer blockbuster hopeful topped Bayers Stivarga in a phase [--] trial Exelixis is shuttering a Pennsylvania site and laying off [---] staffers. $EXEL https://www.fiercebiotech.com/biotech/exelixis-lay-130-employees-shut-down-pennsylvania-site-post-pandemic-downsizing https://www.fiercebiotech.com/biotech/exelixis-lay-130-employees-shut-down-pennsylvania-site-post-pandemic-downsizing"  
[X Link](https://x.com/FierceBiotech/status/1960771025991557421)  2025-08-27T18:26Z 101.7K followers, [----] engagements


"An early clinical studyhas linked Prothenas anti-amyloid beta antibody to a higher rate of brain swelling than rival approved drugs hindering the biotechs positioning in early symptomatic Alzheimers disease. $PRTA https://www.fiercebiotech.com/biotech/prothenas-alzheimers-trial-hit-aria-showstopper-resulting-non-competitive-profile https://www.fiercebiotech.com/biotech/prothenas-alzheimers-trial-hit-aria-showstopper-resulting-non-competitive-profile"  
[X Link](https://x.com/FierceBiotech/status/1961050309276393626)  2025-08-28T12:56Z 101.7K followers, [----] engagements


"Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion through a drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates. $VRTX https://www.fiercebiotech.com/biotech/vertex-forges-2b-alliance-enlaza-create-new-autoimmune-drugs-improve-conditioning-methods https://www.fiercebiotech.com/biotech/vertex-forges-2b-alliance-enlaza-create-new-autoimmune-drugs-improve-conditioning-methods"  
[X Link](https://x.com/FierceBiotech/status/1962892593445908570)  2025-09-02T14:57Z 101.7K followers, [----] engagements


"BioNTech and its new partner BMS have rolled out the first global data for their PD-L1xVEGF bispecific that BioNTechs chief medical officer describes as very consistent with the drugs previous encouraging results from China. $BMY $BNTX https://www.fiercebiotech.com/biotech/biontech-bms-tout-first-global-data-pd-l1xvegf-bispecific-set-phase-3-dose-small-cell-lung https://www.fiercebiotech.com/biotech/biontech-bms-tout-first-global-data-pd-l1xvegf-bispecific-set-phase-3-dose-small-cell-lung"  
[X Link](https://x.com/FierceBiotech/status/1965068433089028323)  2025-09-08T15:03Z 101.7K followers, [----] engagements


"Less than two years after breaking ground on a $1.3 billion R&D center and future U.K. headquarters in London Merck & Co. is bailing on the project and discontinuing all research operations in Britain citing an unwelcoming business environment. $MRK https://www.fiercebiotech.com/biotech/merck-executes-its-own-brexit-moving-all-rd-operations-out-uk https://www.fiercebiotech.com/biotech/merck-executes-its-own-brexit-moving-all-rd-operations-out-uk"  
[X Link](https://x.com/FierceBiotech/status/1965867708618305956)  2025-09-10T19:59Z 101.7K followers, 77.5K engagements


"Regeneron is racing to regulators after reporting a phase [--] win in an ultrarare disease. $REGN https://www.fiercebiotech.com/biotech/regeneron-reports-phase-3-win-ultra-rare-disease-bouncing-back-spark-race-fda https://www.fiercebiotech.com/biotech/regeneron-reports-phase-3-win-ultra-rare-disease-bouncing-back-spark-race-fda"  
[X Link](https://x.com/FierceBiotech/status/1968316885667315780)  2025-09-17T14:11Z 101.7K followers, [----] engagements


"Novo Nordisk hasstruck a deal to buy Akero Therapeutics for up to $5.2 billion teeing up a showdown with Roche and others in a blockbuster liver disease market. https://www.fiercebiotech.com/biotech/novo-inks-52b-akero-buyout-bag-late-phase-mash-prospect https://www.fiercebiotech.com/biotech/novo-inks-52b-akero-buyout-bag-late-phase-mash-prospect"  
[X Link](https://x.com/FierceBiotech/status/1976299761029222533)  2025-10-09T14:52Z 101.7K followers, [----] engagements


"Expedition Therapeutics is gearing up for a phase [--] trek with a $165 million series A https://www.fiercebiotech.com/biotech/expedition-resupplies-phase-2-copd-voyage-165m-series https://www.fiercebiotech.com/biotech/expedition-resupplies-phase-2-copd-voyage-165m-series"  
[X Link](https://x.com/FierceBiotech/status/1976345699488076217)  2025-10-09T17:55Z 101.7K followers, [----] engagements


"Two ex-Moderna leaders have hit a milestone in their new endeavor closing a $325 million inaugural fund for their biotech venture capital firm called Ascenta. https://www.fiercebiotech.com/biotech/2-ex-moderna-leaders-unveil-325m-inaugural-vc-fund-platform-biotechs https://www.fiercebiotech.com/biotech/2-ex-moderna-leaders-unveil-325m-inaugural-vc-fund-platform-biotechs"  
[X Link](https://x.com/FierceBiotech/status/1976374532576509956)  2025-10-09T19:49Z 101.7K followers, [----] engagements


"Bristol Myers Squibb hasagreed to pay $1.5 billion to buy Orbital Therapeutics for a pipeline led by a preclinical CD19 autoimmune program. https://www.fiercebiotech.com/biotech/bms-inks-15b-vivo-car-t-buyout-pull-orbital-its-sphere-influence https://www.fiercebiotech.com/biotech/bms-inks-15b-vivo-car-t-buyout-pull-orbital-its-sphere-influence"  
[X Link](https://x.com/FierceBiotech/status/1976656692688638061)  2025-10-10T14:30Z 101.7K followers, [----] engagements


"Pushing deeper into in vivo cell therapies BMS hasagreed to pay $1.5 billion to buy Orbital Therapeutics for a pipeline led by a preclinical CD19 autoimmune program. $BMY https://www.fiercebiotech.com/biotech/bms-inks-15b-vivo-car-t-buyout-pull-orbital-its-sphere-influence https://www.fiercebiotech.com/biotech/bms-inks-15b-vivo-car-t-buyout-pull-orbital-its-sphere-influence"  
[X Link](https://x.com/FierceBiotech/status/1976668392540270912)  2025-10-10T15:17Z 101.8K followers, [----] engagements


"Gilead Sciences and Arcus Biosciences anti-TIGIT antibody domvanalimab has been tied to median overall survival of close to [--] months keeping alive one of the last remaining hopes for this once-hyped modality. https://www.fiercebiotech.com/biotech/gilead-arcus-keep-tigit-dream-alive-27-month-os-phase-2-cancer-cohort https://www.fiercebiotech.com/biotech/gilead-arcus-keep-tigit-dream-alive-27-month-os-phase-2-cancer-cohort"  
[X Link](https://x.com/FierceBiotech/status/1977804038227075253)  2025-10-13T18:30Z 101.7K followers, [----] engagements


"The FDA has delayed an approval decision for Denali's enzyme replacement therapy designed to treat a rare genetic disorder called Hunter syndrome. The decision has been pushed back three months to April [--]. $DNLI https://www.fiercebiotech.com/biotech/denalis-hunter-syndrome-drug-latest-be-hit-fda-decision-delay https://www.fiercebiotech.com/biotech/denalis-hunter-syndrome-drug-latest-be-hit-fda-decision-delay"  
[X Link](https://x.com/FierceBiotech/status/1978080088273965337)  2025-10-14T12:46Z 101.8K followers, [----] engagements


"Kailera Therapeutics has pulled in one of the largest private fundraises of the year raising $600 million to take its lead obesity program into phase [--]. https://www.fiercebiotech.com/biotech/kailera-taps-bain-led-syndicate-600m-take-zepbound-challenger-phase-3 https://www.fiercebiotech.com/biotech/kailera-taps-bain-led-syndicate-600m-take-zepbound-challenger-phase-3"  
[X Link](https://x.com/FierceBiotech/status/1978099206280696211)  2025-10-14T14:02Z 101.7K followers, [----] engagements


"After Omeros hit pause on developing its MASP-3 inhibitor zaltenibart Novo Nordisk is offering up to $2.1 billion to scoop the rare disease drug. $NVO https://www.fiercebiotech.com/biotech/novo-nordisk-pens-21b-deal-omeros-stalled-pnh-drug https://www.fiercebiotech.com/biotech/novo-nordisk-pens-21b-deal-omeros-stalled-pnh-drug"  
[X Link](https://x.com/FierceBiotech/status/1978469419543404687)  2025-10-15T14:34Z 101.7K followers, [----] engagements


"Lilly shared oral GLP-1 data from two of the remaining three trials in its diabetes program racking up wins against placebo and AstraZenecas Farxiga. $LLY https://www.fiercebiotech.com/biotech/eli-lillys-orforglipron-bests-farxiga-padding-oral-glp-1-case-pair-phase-3-diabetes-wins https://www.fiercebiotech.com/biotech/eli-lillys-orforglipron-bests-farxiga-padding-oral-glp-1-case-pair-phase-3-diabetes-wins"  
[X Link](https://x.com/FierceBiotech/status/1978476406213410869)  2025-10-15T15:01Z 101.7K followers, [----] engagements


"Dianthus is offering Leads Biolabs up to $1 billion biobucks for licensing rights to a 'pipeline in a product' bispecific antibody designed to treat certain autoimmune disorders. $DNTH https://www.fiercebiotech.com/biotech/dianthus-offers-1b-china-biotechs-autoimmune-pipeline-product https://www.fiercebiotech.com/biotech/dianthus-offers-1b-china-biotechs-autoimmune-pipeline-product"  
[X Link](https://x.com/FierceBiotech/status/1978845664990703920)  2025-10-16T15:29Z 101.7K followers, [----] engagements


"A regulatory impasse and the FDAs cancellation of a meeting to discuss the next steps in a R&D program have prompted Kezar Life Sciences to lay off staff and explore strategic alternatives. $KZR https://www.fiercebiotech.com/biotech/kezar-plans-layoffs-after-fda-cancels-meeting-discuss-next-trial https://www.fiercebiotech.com/biotech/kezar-plans-layoffs-after-fda-cancels-meeting-discuss-next-trial"  
[X Link](https://x.com/FierceBiotech/status/1979173632132690421)  2025-10-17T13:12Z 101.7K followers, [----] engagements


"The FDA hashanded out the first nine national priority vouchers positioning companies including Merck KGaA Regeneron and Sanofi to complete the approval process in one to two months. https://www.fiercebiotech.com/biotech/fda-names-regeneron-and-sanofi-among-first-recipients-1-2-month-priority-review-vouchers https://www.fiercebiotech.com/biotech/fda-names-regeneron-and-sanofi-among-first-recipients-1-2-month-priority-review-vouchers"  
[X Link](https://x.com/FierceBiotech/status/1979184792613556610)  2025-10-17T13:56Z 101.7K followers, [----] engagements


"Bristol Myers Squibb is pointing to a 55% overall response rate from one cohort of an early-stage study of its EGFRxHER3 ADC as evidence the pharma can stay ahead of the competition. $BMY https://www.fiercebiotech.com/biotech/esmo-bms-confident-it-can-stay-ahead-competition-adcs-55-orr https://www.fiercebiotech.com/biotech/esmo-bms-confident-it-can-stay-ahead-competition-adcs-55-orr"  
[X Link](https://x.com/FierceBiotech/status/1979199040689434886)  2025-10-17T14:53Z 101.8K followers, [----] engagements


"Big day for biotech newsFierce Biotech has you covered with the largest stories of the morning below: [--]. ESMO: BMS looks to 'stay ahead of the competition' with ADC's 55% response rate in early-stage trial [--]. FDA names nine first recipients of 1- to 2-month priority review vouchers [--]. Licensing galore: Roche Chugai and Kite strike up deals and https://www.fiercebiotech.com/biotech/kite-puts-16b-line-pair-chinas-pregene-another-vivo-car-t-deal https://www.fiercebiotech.com/biotech/licensing-galore-roche-ties-hansoh-adcs-rani-rounds-out-week-chugai-drug-delivery-pact"  
[X Link](https://x.com/FierceBiotech/status/1979215247622787219)  2025-10-17T15:57Z 101.7K followers, [----] engagements


"4. Astellas walks away from gene therapy pact with Taysha before pivotal trial launch [--]. I-Mab undergoes makeover with new name strategy asset and Hong Kong IPO plans https://www.fiercebiotech.com/biotech/i-mab-undergoes-makeover-new-name-strategy-asset-and-hong-kong-ipo-plans https://www.fiercebiotech.com/biotech/astellas-walks-away-gene-therapy-pact-taysha-pivotal-trial-launch https://www.fiercebiotech.com/biotech/i-mab-undergoes-makeover-new-name-strategy-asset-and-hong-kong-ipo-plans https://www.fiercebiotech.com/biotech/astellas-walks-away-gene-therapy-pact-taysha-pivotal-trial-launch"  
[X Link](https://x.com/FierceBiotech/status/1979216372455403855)  2025-10-17T16:02Z 101.7K followers, [----] engagements


"Terns hasshelved its oral GLP-1 obesity candidate after a phase [--] trial fell short of expectations while delivering evidence that the asset causes liver injuries. $TERN https://www.fiercebiotech.com/biotech/terns-mothballs-obesity-program-after-phase-2-data-fall-short https://www.fiercebiotech.com/biotech/terns-mothballs-obesity-program-after-phase-2-data-fall-short"  
[X Link](https://x.com/FierceBiotech/status/1980984664090390858)  2025-10-22T13:08Z 101.8K followers, [----] engagements


"Electra Therapeutics is incandescent glowing on the heels of a $183 million series C financing intended to fuel the biotechs just-launched pivotal trial for its rare disease candidate. https://www.fiercebiotech.com/biotech/some-encouraging-signs-market-electra-shines-183m-fundraise-rare-disease-trial https://www.fiercebiotech.com/biotech/some-encouraging-signs-market-electra-shines-183m-fundraise-rare-disease-trial"  
[X Link](https://x.com/FierceBiotech/status/1980989642779582663)  2025-10-22T13:28Z 101.7K followers, [----] engagements


"Sanofi has dropped its RSV vaccine for toddlers after the candidate underperformed in a phase [--] study. $SNY https://www.fiercebiotech.com/biotech/sanofi-drops-rsv-vaccine-toddlers-after-phase-3-heads-failure https://www.fiercebiotech.com/biotech/sanofi-drops-rsv-vaccine-toddlers-after-phase-3-heads-failure"  
[X Link](https://x.com/FierceBiotech/status/1981715666827702775)  2025-10-24T13:33Z 101.7K followers, [----] engagements


"Just as Adverums cash reserves were running dry Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy. https://www.fiercebiotech.com/biotech/lillys-buys-cash-strapped-adverum-its-phase-3-stage-eye-disease-gene-therapy https://www.fiercebiotech.com/biotech/lillys-buys-cash-strapped-adverum-its-phase-3-stage-eye-disease-gene-therapy"  
[X Link](https://x.com/FierceBiotech/status/1981779518013775976)  2025-10-24T17:47Z 101.7K followers, [----] engagements


"Biogen pens $1B deal for Vanqua's preclinical C5aR1 antagonist https://www.fiercebiotech.com/biotech/biogen-beefs-immunology-pipeline-1b-deal-vanquas-pre-clinical-c5ar1-antagonist https://www.fiercebiotech.com/biotech/biogen-beefs-immunology-pipeline-1b-deal-vanquas-pre-clinical-c5ar1-antagonist"  
[X Link](https://x.com/FierceBiotech/status/1981779911112110179)  2025-10-24T17:48Z 101.7K followers, [----] engagements


"GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. But that dream appears to be over as the pharma shutters the last programs related to this modality. $GSK https://www.fiercebiotech.com/biotech/gsk-abandons-hopes-cd226-cancer-therapies-dropping-remaining-phase-2-assets https://www.fiercebiotech.com/biotech/gsk-abandons-hopes-cd226-cancer-therapies-dropping-remaining-phase-2-assets"  
[X Link](https://x.com/FierceBiotech/status/1983523278401810723)  2025-10-29T13:16Z 101.7K followers, [----] engagements


"After Intellia Therapeutics paused a pair of phase [--] trials for its CRISPR therapy in response to a liver safety signal the FDA has made things official by placing the studies under a clinical hold. $NTLA https://www.fiercebiotech.com/biotech/fda-places-intellia-phase-3-crispr-trials-hold-over-raised-liver-enzymes https://www.fiercebiotech.com/biotech/fda-places-intellia-phase-3-crispr-trials-hold-over-raised-liver-enzymes"  
[X Link](https://x.com/FierceBiotech/status/1983900589366054934)  2025-10-30T14:15Z 101.7K followers, [----] engagements


"Pfizer has approached Metsera with a reworked offer that increases upfront cash consideration for the acquisition from $47.50 to $60 per share for the biotech. $PFE https://www.fiercebiotech.com/biotech/novo-pfizers-bidding-war-metsera-heats-supercharged-offers-obesity-biotech https://www.fiercebiotech.com/biotech/novo-pfizers-bidding-war-metsera-heats-supercharged-offers-obesity-biotech"  
[X Link](https://x.com/FierceBiotech/status/1985732076486705612)  2025-11-04T15:33Z 101.8K followers, [----] engagements


"The FDA hasrejected Biohavens request for approval of a neurological disorder therapy prompting the biopharma to reprioritize its pipeline in order to shrink its annual R&D spend by 60%. $BHVN https://www.fiercebiotech.com/biotech/fda-rejects-biohaven-approval-request-triggering-cost-cutting https://www.fiercebiotech.com/biotech/fda-rejects-biohaven-approval-request-triggering-cost-cutting"  
[X Link](https://x.com/FierceBiotech/status/1986073445554077884)  2025-11-05T14:09Z 101.7K followers, [----] engagements


"Novo Nordisks CEO wont comment on whether the Danish company will go even higher in its bidding war for Metsera but is confident that Novo will close the deal. https://www.fiercebiotech.com/biotech/novo-nordisk-ceo-feels-danish-pharma-will-bag-metsera-end-pfizer-bidding-war https://www.fiercebiotech.com/biotech/novo-nordisk-ceo-feels-danish-pharma-will-bag-metsera-end-pfizer-bidding-war"  
[X Link](https://x.com/FierceBiotech/status/1986077937670467913)  2025-11-05T14:27Z 101.7K followers, [----] engagements


"Following a middling late-stage readout for gastric cancer candidate bemarituzumab Amgen has now stopped a separate phase 1b/3 trial of the molecule. $AMGN https://www.fiercebiotech.com/biotech/amgen-halts-gastric-cancer-trial-after-antibody-did-not-meet-our-standard-efficacy https://www.fiercebiotech.com/biotech/amgen-halts-gastric-cancer-trial-after-antibody-did-not-meet-our-standard-efficacy"  
[X Link](https://x.com/FierceBiotech/status/1986080476335948015)  2025-11-05T14:37Z 101.7K followers, [----] engagements


"Novo Nordisk is winding down a range of early-stage programs for liver disease oncology and stem cells as part of the Danish Pharmas ambitious restructuring. $NVO https://www.fiercebiotech.com/biotech/novo-drops-oncology-ambitions-early-stage-mash-prospects-ongoing-rd-shake https://www.fiercebiotech.com/biotech/novo-drops-oncology-ambitions-early-stage-mash-prospects-ongoing-rd-shake"  
[X Link](https://x.com/FierceBiotech/status/1986084646589731225)  2025-11-05T14:54Z 101.8K followers, [----] engagements


"BMS and J&J havestopped a phase [--] anticoagulant trial early for futility closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales. $BMY $JNJ https://www.fiercebiotech.com/biotech/bms-and-jjs-blood-thinner-flunks-phase-3-denting-big-blockbuster-hopes https://www.fiercebiotech.com/biotech/bms-and-jjs-blood-thinner-flunks-phase-3-denting-big-blockbuster-hopes"  
[X Link](https://x.com/FierceBiotech/status/1989338985542672640)  2025-11-14T14:25Z 101.6K followers, [----] engagements


"Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics obtaining a novel cell death platform while strengthening its prostate cancer franchise built on Erleada. $JNJ https://www.fiercebiotech.com/biotech/jj-buys-halda-cell-death-tech-3b-acquisition-beefing-prostate-cancer https://www.fiercebiotech.com/biotech/jj-buys-halda-cell-death-tech-3b-acquisition-beefing-prostate-cancer"  
[X Link](https://x.com/FierceBiotech/status/1990441092525773121)  2025-11-17T15:25Z 101.6K followers, [----] engagements


"Moderna has binned three more clinical mRNA programs as it aims to reduce R&D spend. $mRNA https://www.fiercebiotech.com/biotech/modernas-reshaping-rolls-3-more-pipeline-purges https://www.fiercebiotech.com/biotech/modernas-reshaping-rolls-3-more-pipeline-purges"  
[X Link](https://x.com/FierceBiotech/status/1991615843588059593)  2025-11-20T21:13Z 101.7K followers, [----] engagements


"Johnson & Johnsons attempt to develop a $5 billion-a-year Alzheimers disease drug has been rocked by a phase [--] flop. $JNJ https://www.fiercebiotech.com/biotech/jjs-5b-alzheimers-hope-fades-anti-tau-antibody-posdinemab-flops-phase-2 https://www.fiercebiotech.com/biotech/jjs-5b-alzheimers-hope-fades-anti-tau-antibody-posdinemab-flops-phase-2"  
[X Link](https://x.com/FierceBiotech/status/1992981059622023467)  2025-11-24T15:38Z 101.7K followers, 94.8K engagements


"With weight loss windfall Lilly looks to become backbone of global innovation https://www.fiercebiotech.com/biotech/weight-loss-windfall-lilly-looks-become-backbone-global-innovation https://www.fiercebiotech.com/biotech/weight-loss-windfall-lilly-looks-become-backbone-global-innovation"  
[X Link](https://x.com/FierceBiotech/status/1998116511618126073)  2025-12-08T19:44Z 101.7K followers, [----] engagements


"Cycle Pharmaceuticals is circling up Applied Therapeutics acquiring the rare disease biotech after an extremely tumultuous year for the latter. $APLT https://www.fiercebiotech.com/biotech/cycle-seizes-struggling-applied-tx-picking-rare-disease-biotech-pennies https://www.fiercebiotech.com/biotech/cycle-seizes-struggling-applied-tx-picking-rare-disease-biotech-pennies"  
[X Link](https://x.com/FierceBiotech/status/1999509193846313145)  2025-12-12T15:58Z 101.7K followers, [----] engagements


"A phase [--] study of AstraZenecas ceralasertib hasmissed its primary endpoint dealing another blow to efforts to use a synthetic lethal mechanism to overcome resistance to I-O drugs. $AZN https://www.fiercebiotech.com/biotech/astrazeneca-flunks-lung-cancer-test-further-setback-synthetic-lethal-mechanism https://www.fiercebiotech.com/biotech/astrazeneca-flunks-lung-cancer-test-further-setback-synthetic-lethal-mechanism"  
[X Link](https://x.com/FierceBiotech/status/2003143952741073091)  2025-12-22T16:41Z 101.7K followers, [----] engagements


"Swirling geopolitical pressures and threatened policy changes did little to abate the pace of China biotech acquisition and licensing deals in [----] and the cumulative value of those deals has never been higher. https://www.fiercebiotech.com/biotech/despite-geopolitical-pressures-china-biotech-deals-remain-pace-collective-value-soars https://www.fiercebiotech.com/biotech/despite-geopolitical-pressures-china-biotech-deals-remain-pace-collective-value-soars"  
[X Link](https://x.com/FierceBiotech/status/2003467060060516461)  2025-12-23T14:05Z 101.7K followers, [----] engagements


"The festive period brought some unwanted news for both Sanofi and Corcept Therapeutics as the FDA delivered rejections for the companies respective drug applications. https://www.fiercebiotech.com/biotech/sanofi-corcept-surprised-fda-rejections-ms-cushings-syndrome-drugs https://www.fiercebiotech.com/biotech/sanofi-corcept-surprised-fda-rejections-ms-cushings-syndrome-drugs"  
[X Link](https://x.com/FierceBiotech/status/2007094264027865560)  2026-01-02T14:18Z 101.7K followers, [----] engagements


"RT @FiercePharma: [--] biopharma CEOs explain why they are 'authentically optimistic' for [----] https://www.fiercepharma.com/pharma/fierce-talks-3-biopharma-ceos-reasons-be-authentically-optimistic-heading-26 https://www.fiercepharma.com/pharma/fierce-talks-3-biopharma-ceos-reasons-be-authentically-optimistic-heading-26"  
[X Link](https://x.com/FierceBiotech/status/2009272830957863102)  2026-01-08T14:35Z 101.7K followers, [--] engagements


"Parabilis Medicines is taking an early lead in the [----] biotech fundraising race closing a $305 million series F round that will fuel a pivotal push for its potential first-in-class cancer drug. https://www.fiercebiotech.com/biotech/parabilis-medicines-rockets-ahead-305m-fundraise-upend-status-quo https://www.fiercebiotech.com/biotech/parabilis-medicines-rockets-ahead-305m-fundraise-upend-status-quo"  
[X Link](https://x.com/FierceBiotech/status/2009281935743295996)  2026-01-08T15:11Z 101.7K followers, [----] engagements


"The life sciences world is once again converging in San Francisco as the J.P. Morgan Healthcare Conference kicks off for [----] and Fierce is here on the ground tracking the biggest biotech deals and industry shifts. Read regular updates from Day [--] here https://www.fiercebiotech.com/biotech/fierce-biotechs-jpm26-tracker-day-1 https://www.fiercebiotech.com/biotech/fierce-biotechs-jpm26-tracker-day-1"  
[X Link](https://x.com/FierceBiotech/status/2010754073394364688)  2026-01-12T16:41Z 101.7K followers, [----] engagements


"RT @FierceHealth: BREAKING: Trump takes aim at insurance industry in unveiling 'The Great Healthcare Plan' https://bit.ly/49Iy9NH https://bit.ly/49Iy9NH"  
[X Link](https://x.com/anyuser/status/2012166104227967093)  2026-01-16T14:12Z 101.7K followers, [--] engagements


"Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public in the latest sign the IPO window is reopening in [----]. https://www.fiercebiotech.com/biotech/immunology-biotech-agomab-eye-focused-spyglass-share-ipo-ambitions https://www.fiercebiotech.com/biotech/immunology-biotech-agomab-eye-focused-spyglass-share-ipo-ambitions"  
[X Link](https://x.com/FierceBiotech/status/2013651232121070018)  2026-01-20T16:34Z 101.7K followers, [----] engagements


"BREAKING: GSK closes the deal on Human Genome Sciences for $3B http://t.co/0i0o0d3L $GSK $HGSI #biotech #pharma PR: http://t.co/YMYS92kh http://bit.ly/M2TPD4 http://bit.ly/NMk0jV http://bit.ly/M2TPD4 http://bit.ly/NMk0jV"  
[X Link](https://x.com/FierceBiotech/status/224862550167273473)  2012-07-16T13:46Z 101.7K followers, [--] engagements


"Buzz: HGS passed up $7B Amgen bid back in the day http://t.co/ea9OPyoO $HGSI $GSK $AMGN #biotech #pharma http://bit.ly/O1IUfW http://bit.ly/O1IUfW"  
[X Link](https://x.com/FierceBiotech/status/228836397417652224)  2012-07-27T12:57Z 101.7K followers, [--] engagements


"Sarepta wants to 'own DMD' in rare disease race with BioMarin. http://t.co/lASkHbrKnp by @DamianFierce $SRPT $BMRN http://www.fiercebiotech.com/story/sarepta-wants-own-dmd-rare-disease-race-biomarin/2015-07-14 http://www.fiercebiotech.com/story/sarepta-wants-own-dmd-rare-disease-race-biomarin/2015-07-14"  
[X Link](https://x.com/FierceBiotech/status/620983626662973442)  2015-07-14T15:50Z 101.7K followers, [--] engagements


"Depression diabetes go hand-in-hand. http://bit.ly/dRVhgf"  
[X Link](https://x.com/FierceBiotech/status/7114682888364032)  2010-11-23T16:54Z 101.7K followers, [--] engagements


"Atlantic Healthcare closes $24M round and gains Salix founder as new CSA. by @PharmaceuticBen $SLXP http://www.fiercebiotech.com/story/atlantic-healthcare-closes-24m-round-and-gains-salix-founder-new-csa/2016-03-21 http://www.fiercebiotech.com/story/atlantic-healthcare-closes-24m-round-and-gains-salix-founder-new-csa/2016-03-21"  
[X Link](https://x.com/FierceBiotech/status/711897756714012674)  2016-03-21T12:50Z 101.7K followers, [--] engagements


"China to pip U.S. researchers to the post on first CRISPR trial: $NVS $EDIT $NLTA http://ow.ly/rfnv302uT3V http://ow.ly/rfnv302uT3V"  
[X Link](https://x.com/FierceBiotech/status/756418399538995200)  2016-07-22T09:19Z 101.7K followers, [--] engagements


"Stem cell biomarker predicts leukemia patients' response to chemo: http://ow.ly/60hc306VF7S http://ow.ly/60hc306VF7S"  
[X Link](https://x.com/FierceBiotech/status/806814204384649220)  2016-12-08T10:54Z 101.7K followers, [--] engagements


"MDB Capital leads I-O startup Cue Biopharma in $26M raise: http://ow.ly/VTBo308ixPr http://ow.ly/VTBo308ixPr"  
[X Link](https://x.com/FierceBiotech/status/823875968142032896)  2017-01-24T12:51Z 101.7K followers, [--] engagements


"Yescarta approved by the FDA last year in the first wave of new CAR-T cell therapies will be teamed up with Pfizers experimental humanized 4-1BB agonist utomilumab in patients with refractory large B-cell lymphoma: $GILD $PFE http://ow.ly/jceh30hRoJe http://ow.ly/jceh30hRoJe"  
[X Link](https://x.com/FierceBiotech/status/954019344664727557)  2018-01-18T15:55Z 101.8K followers, [--] engagements


"Pfizer is swinging the ax again after making big cuts in neurology back in January and includes three tests for utomilumab: $PFE http://ow.ly/518G30jM1nw http://ow.ly/518G30jM1nw"  
[X Link](https://x.com/FierceBiotech/status/991311715647225856)  2018-05-01T13:41Z 101.8K followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing